Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + CHOP
- Development stage
- Unknown
- Lead developer
- The Lymphoma Academic Research Organisation
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
lenalidomide + CHOP is a combination chemotherapy regimen consisting of the immunomodulatory drug lenalidomide and the standard CHOP backbone (cyclophosphamide, doxorubicin, vincristine, and prednisone). Lenalidomide is a small molecule that binds to the cereblon E3 ubiquitin ligase complex, leading to the degradation of transcription factors like Ikaros (IKZF1) and Aiolos (IKZF3), which results in antiproliferative and immunomodulatory effects. CHOP is a multi-agent chemotherapy regimen that targets DNA replication and microtubule assembly. This specific combination was evaluated by The Lymphoma Academic Research Organisation (LYSARC) as a first-line treatment for elderly patients (aged 60-80) with angioimmunoblastic T-cell lymphoma (AITL). In clinical trials, the regimen aimed to improve complete metabolic response rates, although results indicated it did not significantly outperform historical controls in this specific population.
- Brand names
- RevlimidCytoxanAdriamycinOncovin
- Other names
- lenalidomide plus CHOPlenalidomide + cyclophosphamide + doxorubicin + vincristine + prednisone
02
Targets
TOP2A (DNA topoisomerase II)CRBN (Cereblon)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on lenalidomide + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + CHOP.